echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Nat Commun: Long-term use of Dasatinib and Quercetin can improve intervertebral disc degeneration 

    Nat Commun: Long-term use of Dasatinib and Quercetin can improve intervertebral disc degeneration 

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    With the extension of human life span, the incidence and impact of age-dependent diseases are also increasing
    .


    In the recent global survey of 50 chronic diseases, low back pain (LBP) and neck pain ranked first and fourth respectively in terms of years of being unable to take care of themselves


    The intervertebral disc is flexible and plays a key role in adapting to the mechanical load of the spine
    .


    These functional properties are achieved by the interaction of three unique intervertebral disc compartments: the central nucleus pulposus (NP) -avascular tissue, rich in lectins; the circumferential ligament-like fibrous ring (AF)-mainly composed of collagen fibers Composition; and the cartilage inner plate (CEP) bordering the craniofacial and caudal surfaces of NP and AF


    Blood vessel

    The characteristics of intervertebral disc degeneration include decreased abundance and quality of extracellular matrix (ECM), loss of biomechanical properties, increased inflammatory mediators and catabolic processes, and changes in cell phenotype and death
    .


    Although the prevalence and disease burden are widespread, there is currently no disease treatment for intervertebral disc degeneration and related disorders


    The characteristics of intervertebral disc degeneration include a decrease in the abundance and quality of extracellular matrix (ECM), loss of biomechanical properties, an increase in inflammatory mediators and catabolic processes, and changes in cell phenotype and death.


    Studies on human tissues and mouse models have shown that the incidence of senescent cells increases during the aging and degeneration of intervertebral discs
    .


    The broad characteristics of senescent cells are cell cycle arrest, resistance to apoptosis, and production of catabolic factors called senescence-associated secreted phenotype (SASP)


    The broad characteristics of senescent cells are cell cycle arrest, anti-apoptosis, and production of catabolic factors called senescence-associated secreted phenotype (SASP).


    The aging drugs Dasatinib and Quercetin can reduce age-dependent disc degeneration and reduce the abundance of aging markers

    The aging drugs Dasatinib and Quercetin can reduce age-dependent disc degeneration and reduce the abundance of aging markers.
    The aging drugs Dasatinib and Quercetin can reduce age-dependent disc degeneration and reduce the abundance of aging markers.

    Recently, due to the link between intervertebral disc degeneration and aging, researchers have explored the ability of the anti-aging drug Dasatinib and Quercetin (D + Q) to prevent the age-dependent progression of the body's intervertebral disc degeneration
    .

    The researchers started treatment with C57BL/6 mice at 6, 14 and 18 months of age and analyzed them at 23 months of age
    .


    Interestingly, the 6-month and 14-month D + Q cohorts showed a lower incidence of degeneration , and treatment resulted in a significant reduction in the aging markers p16INK4a and p19ARF, as well as the SASP molecules IL-6 and MMP13


    The 6-month and 14-month D+Q cohort showed a lower incidence of degeneration.


    Aging drugs may provide an attractive strategy to reduce age-dependent disc degeneration


    Original source:

    Original source:

    Emanuel J.


    Emanuel J.


     

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.